Tutorials
PDL BioPharma Inc logo

PDL BioPharma Inc

$ 2.47 0 (0%) 09:40 AM EST
P/E:
At Loss
P/B:
0
Market Cap:
$ 282.14M
Enterprise V:
$ 282.14M
Volume:
-
Avg Vol (2M):
-
Also Trade In:
Volume:
-
Market Cap $:
282.14M
PE Ratio:
At Loss
Avg Vol (2-Month):
-
Enterprise Value $:
282.14M
PB Ratio:
0
GF Score:
Year:
EMBED
To
10Y: -%
Above Low: +NaN%
Below High: NaN%
Alerts Website SEC Filings Stock Report
Dataset
Financial Download Tutorials

Business Description

PDL BioPharma Inc
NAICS : 325412 SIC : 2836
932 Southwood Boulevard, Incline Villiage, NV, USA, 89451
Description
PDL BioPharma Inc acquires and manages a portfolio of companies, products, royalty agreements and debt facilities in the biotech, pharmaceutical and medical device industries. The operating segments of the company are Medical Devices, Strategic Positions, Pharmaceutical and Income Generating Assets, of which key revenue is derived from the Pharmaceutical segment. The Pharmaceutical segment consists of revenue derived from branded prescription medicine products sold under the name Tekturna and Tekturna HCT in the U.S, and Rasilez and Rasilez HCT in the rest of the world (collectively, the Noden Products). Geographically, the company operates in Europe, North America, Asia and Other countries, of which prime revenue is generated from Asia and North America.

Financial Strength

Name Current Vs Industry Vs History
Piotroski F-Score 0/9
0
1
2
3
4
5
6
7
8
9
Altman Z-Score 0
Distress
Grey
Safe
Beneish M-Score 0
Manipulator
Not Manipulator

Growth Rank

Name Current Vs Industry Vs History

Momentum Rank

Name Current Vs Industry Vs History
6-1 Month Momentum % -4.86
12-1 Month Momentum % 5.93

Liquidity Ratio

Name Current Vs Industry Vs History

Dividend & Buy Back

Name Current Vs Industry Vs History

Profitability Rank

Name Current Vs Industry Vs History

GF Value Rank

Name Current Vs Industry Vs History

Financials (Next Earnings Date:2022-11-09 Est.)

PDLI's 30-Y Financials

Guru Trades

See Details
To
EMBED
SAVE

Insider Trades

See Details
To
EMBED
SAVE

Gurus Latest Trades with NAS:PDLI

Peter Lynch Chart

Y-axis scale:
Interactive Chart
To
EMBED
SAVE
Dividend
To
EMBED
SAVE

Annualized Return %

Symbol 1 Week 1 Month 3 Months 6 Months YTD 1 Year 3 Years 5 Years 10 Years

Total Annual Return %

Symbol 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013

Executives

EMBED

Valuation Box

Year:
EMBED

Analyst Estimate

Key Statistics

Name Value
Revenue (TTM) (Mil $) 49.576
EPS (TTM) ($) -1.33
Beta 0
Volatility % 48.88
14-Day RSI 0
14-Day ATR ($) 0
20-Day SMA ($) 0
12-1 Month Momentum % 5.93
52-Week Range ($) 1.897767 - 3.498522
Shares Outstanding (Mil) 114.23

Piotroski F-Score Details

Year:
Component Result
Piotroski F-Score 0
Positive ROA
Positive CFROA
Higher ROA yoy
CFROA > ROA
Lower Leverage yoy
Higher Current Ratio yoy
Less Shares Outstanding yoy
Higher Gross Margin yoy
Higher Asset Turnover yoy

PDL BioPharma Inc Filings

Document Form Filing Date
No Filing Data

Headlines

See More